Child with Wiskott–Aldrich syndrome underwent atypical immune reconstruction after umbilical cord blood transplantation: A case report

Table 1 Details of human leukocyte antigen matching

	Patient 0	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
HLA-A(patient/donor)	02:07 11:02	02:01 33:03	02:07 30:01	24:20 30:01	32:01 11:01	03:01 01:01
	02:07 24:02	02:06 33:03	02:07 30:01	24:20 31:01	32:01 02:06	03:01 32:01
HLA-B(patient/donor)	54:01 40:02	40:06 58:01	13:02 46:01	13:02 40:01	44:03 48:01	27:05 57:01
	54:01 56:01	40:06 58:01	13:02 46:01	13:02 40:01	44:03 48:01	27:05 57:01
HLA-C(patient/donor)	01:02 07:02	03:02 08:01	01:02 06:02	06:02 07:02	04:01 08:01	02:02 06:02
	01:02 07:02	03:02 08:01	01:02 06:02	06:02 07:02	04:01 08:01	02:02 06:02
HLA-DRB1(patient/donor)	14:54 12:02	03:01 09:01	07:01 09:01	07:01 08:03	07:01 15:01	15:01 11:04
	14:55 12:02	03:01 09:01	07:01 09:01	07:01 08:03	07:01 15:01	15:01 10:01
HLA-DQB1(patient/donor)	05:03 03:02	02:01 03:03	02:02 03:03	02:02 06:01	02:02 06:02	03:01 03:01
	05:03 03:01	02:01 03:03	02:02 03:03	02:02 06:01	02:02 05:03	05:01 06:02
Matches	6/10	9/10	10/10	9/10	8/10	6/10

HLA: Human leukocyte antigen.

Table 2 Details of drug use

The conditioning regimen	Bu + FLu + CTX + ATG	BU 1.0 mg/kg, day-9 to day-6; FLu, 40 mg/m2, day-5 to day-2; CTX, 60 mg/kg, day-5 to day-4; ATG 2.5 mg/kg, qd, day-8 to day-5
Prophylaxis for GVHD	CSA + MMF	CSA (6-8 mg/kg/d) and MMF (20 mg/kg/d)
Preventing hepatic VOD	Heparin and alprostadil
Preventing infection	Ganciclovir, acyclovir, micafungin and meropenem

Flu: Fludarabine; CTX: Cyclophosphamide; BU: Busulfan; ATG: Antithymocyte globulin; GVHD: Graft versus host disease; CSA: Cyclosporin A; MMF: Mycophenolate mofetil; VOD: Vein occlusion disease.

Table 3 Basic clinical parameters of five other umbilical cord blood transplantation patients

	Patient 0 (case)	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Age in yr	1	4	< 1 (8 m)	1	5	2
Sex	Male	Male	Male	Male	Male	Male
Time for UCBT	2017/10/15	2017/6/3	2018/6/8	2018/3/24	2017/7/7	2017/12/15
CD34 dose	4.7 × 105/kg	2 × 105/kg	4.92 × 105/kg	2.4 × 1055/kg	4.55 × 105/kg	3.0 × 105/kg
TNC	9.17 × 107/kg	6.73 × 107/kg	15.3 × 107/kg	11.1 × 107/kg	6.26 × 107/kg	9.23 × 107/kg
Conditional regimen	Bu + Flu + CTX + ATG	BU + Flu + CTX + ATG	BU + Flu + CTX + ATG	BU + Flu + CTX + ATG	BU + Flu + CTX + ATG	BU + Flu + CTX + ATG
HLA (/6)	4/6	6/6	6/6	5/6	5/6	4/6
HLA (/10)	6/10	9/10	10/10	9/10	8/10	6/10
Blood type (patient/donor)	B/B	A/O	B/B	O/O	O/O	A/AB
Neutrophil grafted time	D34	D16	D13	D15	D17	D14
Lymphocytes>0.5 × 109/L	D23	D28	D42	D17	D30	D65
PLT grafted time	D66	D28	D29	D30	D33	D27
Main complication	No	Hemorrhagic cystitis	Infection by Pneumocystis carinii	No	Intestinal infection	Leak syndrome, hemorrhagic cystitis

Flu: Fludarabine; CTX: Cyclophosphamide; BU: Busulfan; ATG: Antithymocyte globulin.

Table 4 Details of short tandem repeats

Day	PB or BM	STR
14	PB	76.80%
24	PB	98.60%
31	PB	99.10%
38	PB	98.80%
45	PB	99.30%
52	PB	98.80%
60	PB	99.30%
66	PB	98.60%
75	PB	98.70%
102	PB	98.70%
17	BM	62.30%
26	BM	98.10%
43	BM	98.70%

STR: Short tandem repeat; PB: Peripheral blood; BM: Bone marrow.